BackgroundFatty liver is a major metabolic disorder in dairy cows and is believed to result in major economic losses in dairy farming due to decreased health status, reproductive performance and fertility. Currently, the definitive means for diagnosing fatty liver is determining the fat content of hepatic tissue by liver biopsy, which is an invasive and costly procedure, making it poorly suited to dairy farms. Therefore, the key aim of this study was to investigate the measurement of serum paraoxonase-1 (PON1), an enzyme exclusively synthesized by the liver, as a sensitive noninvasive biomarker for diagnosis of fatty liver in dairy cows.ResultsA comparative cohort study using serum specimens from Holstein–Friesian dairy cows (46 healthy and 46 fatty liver cases) was conducted. Serum PON1 (paraoxonase, lactonase and arylesterase) activity and other biochemical and hematological parameters were measured. We found that serum PON1 activity was lower (P<0.001) in cows suffering from fatty liver. The area under the receiver operating characteristic curve (AUC-ROC) of PON1 activity for diagnosis of fatty liver was 0.973–0.989 [95% confidence interval (CI) 0.941, 1.000] which was higher than the AUC-ROC of aspartate aminotransferase (AST), lecithin-cholesterol acyltransferase (LCAT), alkaline phosphatase (ALP), non-esterified fatty acids (NEFA), beta-hydroxybutyrate (BHBA), total cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein (LDL). We found that adding serum PON1 measurement to different batteries of serum diagnostic panels showed a combination of high sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (+LR), negative likelihood ratio (−LR), diagnostic odd ratio (DOR) and overall diagnostic accuracy in diagnosing fatty liver.ConclusionsThe present results indicate that addition of serum PON1 activity measurement to the biochemical profile could improve the diagnosis of fatty liver in dairy cows, which would have a considerable clinical impact and lead to greater profitability in the dairy industry.
Immune responses mounted against T. spiralis infection in rats were associated with hepatic inflammation and a subsequent decrease in serum PON1 and BuChE activities.
Infections with gastrointestinal nematodes provoke immune and inflammatory responses
mediated by cytokines released from T-helper type-2 (Th2) cells. Infections with
Trichinella
species have been reported to differ by the host species.
Previously, in rats, we observed acute liver inflammation in response to infection with
Trichinella spiralis
, and the rat hosts showed a series of biochemical
changes characterized by a decrease in serum paraoxonase (PON) 1 activity associated with
the down-regulation of hepatic PON1 synthesis. In the present study, we investigated the
effect(s) of species differences on the immune response against
T.
spiralis
infection by analyzing serum PON1 activity and the associated
inflammatory/anti-inflammatory mediators in mice. There were inconsistent changes in the
serum PON1 activity of mice infected with
T. spiralis
, and these changes
were associated with significant increases in the serum levels of interleukin (IL)-2,
IL-4, IL-10, IL-12 (p70), granulocyte-macrophage colony-stimulating factor, and tumor
necrosis factor α during the enteric phase of the infection, while the levels of IL-5 and
interferon γ were significantly increased throughout the entire experimental period.
Moreover,
T. spiralis
infection in mice was associated with little
inflammatory cell infiltration in hepatic tissues. Given the zoonotic prevalence of
T. spiralis
, further mechanistic research in this area is
warranted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.